Is Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) a buy in 2026?
Lean no. The Compass would trim Apellis Pharmaceuticals, Inc. here, not add.
Biogen's buyout caps the upside at $41.03. The arb spread is gone, the optionality belongs to Biogen shareholders now.
Where APLS is headed
Apellis stopped being a stock and became a closing document on May 14, 2026, when Biogen completed the acquisition. The shares trade at $41.03, the 52-week high is $41.14, and the analyst target mean sits at $40.92 with a high of $41.00. That is what a stock looks like when the deal price is set and the tender has cleared. Whatever happens to SYFOVRE in geographic atrophy, whatever EMPAVELI does in C3 glomerulopathy, whatever the Beam base-editing collaboration produces in the next decade, those outcomes accrue to Biogen (NASDAQ:BIIB) shareholders. Not to anyone buying APLS at $41 today.
Read the full Compass Direction on APLS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $41.03).
See the full APLS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) a buy in 2026?
Lean no. The Compass would trim Apellis Pharmaceuticals, Inc. here, not add. Biogen's buyout caps the upside at $41.03. The arb spread is gone, the optionality belongs to Biogen shareholders now.
What is APLS's Compass Score?
Apellis Pharmaceuticals, Inc. scores 83/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for APLS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the APLS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.